AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32435908 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical transnasal endoscopic DCR (MTE-DCR)
Number of subjects: 29
Study 32435908 — intervention group
Group type: COMPARATOR
Intervention: Transcanalicular dacryocystorhinostomy with multidiode laser (TCML-DCR)
Number of subjects: 29
Study 32536496 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback training using PocketCPR
Number of subjects: 64
Study 32536496 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback training using Skill Reporter
Number of subjects: 64
Study 32536496 — intervention group
Group type: COMPARATOR
Intervention: Non-feedback training (control group)
Number of subjects: 64
Study 32536496 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback training (both methods)
Number of subjects: 64
Study 34989637 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of a tourniquet and buffered lidocaine solution (CTB)
Number of subjects: 169
Study 34989637 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide awake local anesthesia no tourniquet (WALANT)
Number of subjects: 169
Study 34989637 — intervention group
Group type: COMPARATOR
Intervention: Conventional local anesthesia (LA)
Number of subjects: 169
Study 32952089 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-item likelihood of proactive use scale
Number of subjects: 0
Study 32952089 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-item measure of confidence in use of insurance
Number of subjects: 0
Study 34736360 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% 1RM in hypoxia
Number of subjects: 15
Study 34736360 — intervention group
Group type: COMPARATOR
Intervention: 30% 1RM in normoxia
Number of subjects: 15
Study 34736360 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% 1RM in hypoxia
Number of subjects: 15
Study 34736360 — intervention group
Group type: COMPARATOR
Intervention: 70% 1RM in normoxia
Number of subjects: 15
Study 34736360 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% 1RM
Number of subjects: 15
Study 34736360 — intervention group
Group type: COMPARATOR
Intervention: 30% 1RM
Number of subjects: 15
Study 34496924 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 80
Study 34496924 — intervention group
Group type: COMPARATOR
Intervention: Conservative medical treatment (control group)
Number of subjects: 80
Study 35064301 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block
Number of subjects: 40
Study 35064301 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 34015311 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant durvalumab monotherapy
Number of subjects: 60
Study 34015311 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant durvalumab plus stereotactic body radiotherapy (8 Gy × 3 fractions)
Number of subjects: 60
Study 34015311 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant durvalumab plus stereotactic body radiotherapy
Number of subjects: 60
Study 34953451 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish massage (30-min sessions, twice a week for first 4 weeks, three times a week for last 4 weeks)
Number of subjects: 60
Study 34953451 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 60
Study 32989866 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold atmospheric plasma (CAP) treatment once a week (Group 1)
Number of subjects: 37
Study 32989866 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold atmospheric plasma (CAP) treatment twice a week (Group 2)
Number of subjects: 37
Study 32989866 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy once a week (Group 3)
Number of subjects: 37
Study 34031890 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (50 mg for 7 days)
Number of subjects: 711
Study 34031890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 711
Study 36216748 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior (30 minutes more)
Number of subjects: 1918
Study 36216748 — intervention group
Group type: EXPERIMENTAL
Intervention: Light physical activity (30 minutes more)
Number of subjects: 1918
Study 36216748 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep (30 minutes less)
Number of subjects: 1918
Study 33992438 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces cerevisiae recombinant hepatitis B vaccine (Group D20SC 0-1-6)
Number of subjects: 309
Study 33992438 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese hamster ovary cell (CHO) recombinant hepatitis B vaccine (Group D20CHO 0-1-6)
Number of subjects: 309
Study 33992438 — intervention group
Group type: COMPARATOR
Intervention: Saccharomyces cerevisiae recombinant hepatitis B vaccine (Group ND20SC 0-1-6)
Number of subjects: 309
Study 32416834 — intervention group
Group type: EXPERIMENTAL
Intervention: LASER
Number of subjects: 1200
Study 32416834 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1200
Study 34935711 — intervention group
Group type: EXPERIMENTAL
Intervention: Toric intraocular lens (TIOL) implantation
Number of subjects: 75
Study 34935711 — intervention group
Group type: COMPARATOR
Intervention: Femtosecond laser‐assisted arcuate keratotomy (FSAK)
Number of subjects: 75
Study 32602970 — intervention group
Group type: EXPERIMENTAL
Intervention: TARC-2 >800 pg/mL
Number of subjects: 266
Study 32602970 — intervention group
Group type: EXPERIMENTAL
Intervention: TARC-2 ≤800 pg/mL
Number of subjects: 266
Study 32602970 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-2-negative patients with elevated TARC-2
Number of subjects: 266
Study 32602970 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-2-negative patients without elevated TARC-2
Number of subjects: 266
Study 32602970 — intervention group
Group type: EXPERIMENTAL
Intervention: TARC-2 >800 pg/mL (whole study population)
Number of subjects: 266
Study 32602970 — intervention group
Group type: EXPERIMENTAL
Intervention: TARC-2 >800 pg/mL (PET-2-negative patients)
Number of subjects: 266
Study 32887560 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced education via WeChat app
Number of subjects: 0
Study 32887560 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 0
Study 36281170 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose doxepin (6.25 mg-12.5 mg per day) for 12 weeks
Number of subjects: 49
Study 34551869 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P59 20 mg/kg
Number of subjects: 50
Study 32713405 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-specific ICT and if-then planning
Number of subjects: 78
Study 32713405 — intervention group
Group type: EXPERIMENTAL
Intervention: General ICT and if-then planning
Number of subjects: 78
Study 32713405 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT and if-then planning (both groups)
Number of subjects: 78
Study 32713405 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT and if-then planning
Number of subjects: 78
Study 33518123 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature/RH combination of -15°C with uncontrolled RH for 8 hours
Number of subjects: 240
Study 33518123 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature/RH combination of 30°C with 80% RH for 8 hours
Number of subjects: 240
Study 33518123 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature/RH combination of 30°C with 30% RH for 8 hours
Number of subjects: 240
Study 33518123 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature/RH combinations (21/30, 21/80, 30/30, 30/80)
Number of subjects: 240
Study 33518123 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of exposure (4 or 8 hours)
Number of subjects: 240
Study 35446986 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for PTSD
Number of subjects: 318
Study 35446986 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for depression
Number of subjects: 318
Study 35446986 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for PTSD and depression
Number of subjects: 318
Study 33861314 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN) with HALO‐AI analysis
Number of subjects: 187
Study 33861314 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN) for autoimmune gastritis (AG)
Number of subjects: 187
Study 33861314 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN) for Helicobacter pylori gastritis (HPG)
Number of subjects: 187
Study 33861314 — intervention group
Group type: COMPARATOR
Intervention: GI pathologists
Number of subjects: 187
Study 33861314 — intervention group
Group type: COMPARATOR
Intervention: General surgical pathologists
Number of subjects: 187
Study 33861314 — intervention group
Group type: COMPARATOR
Intervention: Residents
Number of subjects: 187
Study 35676030 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid (ω3FA) supplementation (4 g/day)
Number of subjects: 0
Study 35676030 — intervention group
Group type: COMPARATOR
Intervention: No ω3FA treatment (Control)
Number of subjects: 0
Study 33894423 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OXT)
Number of subjects: 121
Study 33894423 — intervention group
Group type: COMPARATOR
Intervention: Placebo intranasal spray
Number of subjects: 121
Study 33894423 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (decreased 5-HT signaling)
Number of subjects: 121
Study 33894423 — intervention group
Group type: COMPARATOR
Intervention: Placebo control protocol (normal 5-HT signaling)
Number of subjects: 121
Study 32349761 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-stand desk intervention (6 sit-stand desks replacing 3 standard desks for 4.5 months)
Number of subjects: 176
Study 32349761 — intervention group
Group type: COMPARATOR
Intervention: Usual practice control arm
Number of subjects: 176
Study 35617462 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based TCCC tourniquet application training (Group A, n = 25)
Number of subjects: 43
Study 35617462 — intervention group
Group type: COMPARATOR
Intervention: Simulation-based TCCC tourniquet application training (Group B, n = 18)
Number of subjects: 43
Study 33638278 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive online informational and peer support app for LARS
Number of subjects: 0
Study 32323190 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg once daily
Number of subjects: 12729
Study 32323190 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 12729
Study 33966671 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved technique with glove change after each N95 contact
Number of subjects: 12
Study 33966671 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐minute ultraviolet‐C light (UV‐C) treatment prior to donning
Number of subjects: 12
Study 33966671 — intervention group
Group type: COMPARATOR
Intervention: Control with suboptimal respirator handling technique
Number of subjects: 12
Study 33900373 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based educational intervention
Number of subjects: 119
Study 33900373 — intervention group
Group type: COMPARATOR
Intervention: Upper GI tract endoscopy (control)
Number of subjects: 119
Study 32998766 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin-guided donation intervals policy (including ferritin measurements for all new donors and at every 5th whole blood donation, extending donation intervals to 6 months if ferritin is 15-≤ 30 ng/mL and to 12 months if ferritin is < 15 ng/mL)
Number of subjects: 29
Study 32998766 — intervention group
Group type: COMPARATOR
Intervention: Existing policy without ferritin measurements
Number of subjects: 29
Study 34186022 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 478
Study 34186022 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 478
Study 34186022 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 478
Study 34186022 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide (all doses)
Number of subjects: 478
Study 34186022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 478
Study 32412419 — intervention group
Group type: EXPERIMENTAL
Intervention: FOOTFIT (nonexertive physical conditioning activities for lower leg function)
Number of subjects: 24
Study 32412419 — intervention group
Group type: COMPARATOR
Intervention: FOOTFIT+ (FOOTFIT with added patient-provider communication feature)
Number of subjects: 24
Study 36104378 — intervention group
Group type: EXPERIMENTAL
Intervention: Luseogliflozin (2.5 mg daily)
Number of subjects: 157
Study 36104378 — intervention group
Group type: COMPARATOR
Intervention: Voglibose (0.6 mg daily)
Number of subjects: 157
Study 34118103 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire rope guide with chin lift (wire group)
Number of subjects: 100
Study 34118103 — intervention group
Group type: COMPARATOR
Intervention: Control technique of head flexion (control group)
Number of subjects: 100
Study 32797232 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐CIESI with triamcinolone
Number of subjects: 120
Study 32797232 — intervention group
Group type: COMPARATOR
Intervention: CTFESI with dexamethasone
Number of subjects: 120
Study 35369715 — intervention group
Group type: COMPARATOR
Intervention: Substernal chest pain (reference group)
Number of subjects: 9996
Study 35369715 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnea
Number of subjects: 9996
Study 35369715 — intervention group
Group type: EXPERIMENTAL
Intervention: Other symptoms
Number of subjects: 9996
Study 35369715 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive noninvasive test
Number of subjects: 9996
Study 34597324 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP ventilation and passive CPAP oxygenation
Number of subjects: 68
Study 34597324 — intervention group
Group type: COMPARATOR
Intervention: Control (no positive airway pressure)
Number of subjects: 68
Study 35418599 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenite 6 mg/l
Number of subjects: 0
Study 35418599 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenite 8 mg/l
Number of subjects: 0
Study 35418599 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenite 10 mg/l
Number of subjects: 0
Study 35418599 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano-selenium 12 mg/l
Number of subjects: 0
Study 35418599 — intervention group
Group type: COMPARATOR
Intervention: Control (distilled water)
Number of subjects: 0
Study 35418599 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenite 6 mg/l and 8 mg/l
Number of subjects: 0
Study 33530059 — intervention group
Group type: EXPERIMENTAL
Intervention: X-Stop interspinous distractor device
Number of subjects: 47
Study 33530059 — intervention group
Group type: COMPARATOR
Intervention: Laminectomy
Number of subjects: 47
Study 36134907 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue flossing (FLOSS)
Number of subjects: 32
Study 36134907 — intervention group
Group type: COMPARATOR
Intervention: Foam rolling (ROLL)
Number of subjects: 32
Study 34362264 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg
Number of subjects: 90
Study 34362264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 34362264 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD shock (at least one)
Number of subjects: 90
Study 34362264 — intervention group
Group type: COMPARATOR
Intervention: No ICD shock
Number of subjects: 90
Study 32940343 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 0
Study 32940343 — intervention group
Group type: COMPARATOR
Intervention: Fumaric acid esters
Number of subjects: 0
Study 32940343 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 0
Study 32663354 — intervention group
Group type: EXPERIMENTAL
Intervention: RFS-nomogram based on tumor size, differentiation, microscopic vascular invasion, preoperative α-fetoprotein, neutrophil-to-lymphocyte ratio, albumin-to-bilirubin ratio, and blood transfusion
Number of subjects: 1081
Study 32663354 — intervention group
Group type: EXPERIMENTAL
Intervention: OS-nomogram based on tumor size, differentiation, microscopic vascular invasion, preoperative α-fetoprotein, neutrophil-to-lymphocyte ratio, albumin-to-bilirubin ratio, and blood transfusion
Number of subjects: 1081
Study 35983622 — intervention group
Group type: EXPERIMENTAL
Intervention: Daprodustat
Number of subjects: 50
Study 35983622 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study 33848778 — intervention group
Group type: EXPERIMENTAL
Intervention: bSPECT/CT imaging
Number of subjects: 43
Study 33848778 — intervention group
Group type: COMPARATOR
Intervention: PET/CT imaging
Number of subjects: 43
Study 34025030 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan (20 mg/day)
Number of subjects: 216
Study 34025030 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole (30 mg/day)
Number of subjects: 216
Study 32031904 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV patients accessing antiretroviral treatment
Number of subjects: 200
Study 35768650 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg every 4 weeks (Q4W)
Number of subjects: 381
Study 35768650 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg at Week 0, Week 4, then every 8 weeks (Q8W)
Number of subjects: 381
Study 35768650 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 381
Study 33567129 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltitrexed (3 mg/m2 from day 1 every 3 weeks) and oral S‐1 (80‐120 mg for 14 days every 3 weeks)
Number of subjects: 105
Study 33567129 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltitrexed combined with S-1 (RS regimen)
Number of subjects: 105
Study 35666800 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mg of 0.1% E2 gel daily
Number of subjects: 78
Study 35666800 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 78
Study 33152704 — intervention group
Group type: EXPERIMENTAL
Intervention: PET/CT
Number of subjects: 799
Study 33152704 — intervention group
Group type: COMPARATOR
Intervention: SoC (CT CAP and bone scan)
Number of subjects: 799
Study 35031887 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa flavanols (415 mg)
Number of subjects: 80
Study 34238546 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 35
Study 34238546 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodynamic therapy to achieve individualised preoperative DO2
Number of subjects: 35
Study 35303025 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher initial levels of shame
Number of subjects: 110
Study 35303025 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial levels of guilt
Number of subjects: 110
Study 35303025 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher initial levels of other drug use
Number of subjects: 110
Study 32023543 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR) at 45% of resting pulse elimination pressure
Number of subjects: 0
Study 32023543 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (0% BFR)
Number of subjects: 0
Study 33428581 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning module
Number of subjects: 75
Study 33428581 — intervention group
Group type: COMPARATOR
Intervention: Traditional didactic video
Number of subjects: 75
Study 32217524 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthoses
Number of subjects: 218
Study 32217524 — intervention group
Group type: COMPARATOR
Intervention: Hip exercises
Number of subjects: 218
Study 32217524 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthoses (high midfoot width mobility)
Number of subjects: 218
Study 32217524 — intervention group
Group type: COMPARATOR
Intervention: Hip exercises (high midfoot width mobility)
Number of subjects: 218
Study 32217524 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthoses (low midfoot width mobility)
Number of subjects: 218
Study 32217524 — intervention group
Group type: COMPARATOR
Intervention: Hip exercises (low midfoot width mobility)
Number of subjects: 218
Study 34931479 — intervention group
Group type: EXPERIMENTAL
Intervention: ESAS-screened
Number of subjects: 119806
Study 34931479 — intervention group
Group type: COMPARATOR
Intervention: Not screened (Control)
Number of subjects: 119806
Study 34812863 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular Platelet-Rich Plasma (PRP) injections (n=144 participants)
Number of subjects: 288
Study 34812863 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo injections (n=144 participants)
Number of subjects: 288
Study 34091814 — intervention group
Group type: EXPERIMENTAL
Intervention: INVOS 5100C (Medtronic, Minneapolis, MN, USA)
Number of subjects: 70
Study 34091814 — intervention group
Group type: COMPARATOR
Intervention: FORE-SIGHT ELITE (CAS Medical Systems, Branford, CT, USA)
Number of subjects: 70
Study 34475964 — intervention group
Group type: EXPERIMENTAL
Intervention: Qishen Yiqi dripping pills (QSYQ) for 12 weeks
Number of subjects: 66
Study 34475964 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 66
Study 35839499 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel processing for induction of anesthesia and OR cleaning with sugammadex
Number of subjects: 111
Study 35839499 — intervention group
Group type: COMPARATOR
Intervention: Traditional linear processing for induction of anesthesia and OR cleaning with neostigmine/glycopyrrolate
Number of subjects: 111
Study 33781280 — intervention group
Group type: EXPERIMENTAL
Intervention: Blueberry supplementation (BLU)
Number of subjects: 11
Study 33781280 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 11
Study 32275024 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural (TEA) with 0.25% bupivacaine and continuous infusion of 0.1% bupivacaine with 2 mcg/ml of fentanyl.
Number of subjects: 0
Study 32275024 — intervention group
Group type: COMPARATOR
Intervention: Intercostal block (ICN) with 0.25% bupivacaine and continuous intravenous morphine infusion of 0.015‐0.02 mg/kg/hr.
Number of subjects: 0
Study 34501882 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including a Garmin watch, under-desk pedal machine, and management support
Number of subjects: 22
Study 34501882 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 22
Study 34501882 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus groups for acceptability assessment
Number of subjects: 22